Safety Study of Nexvax2 in Subjects With Coeliac Disease
Phase 1
Completed
- Conditions
- Coeliac DiseaseCeliac Disease
- Interventions
- Other: PlaceboBiological: 9 micrograms Nexvax2Biological: 30 micrograms Nexvax2Biological: 90 micrograms Nexvax2Biological: 60 micrograms Nexvax2Biological: Up to 900 micrograms Nexvax2
- First Posted Date
- 2009-04-10
- Last Posted Date
- 2011-04-07
- Lead Sponsor
- Nexpep Pty Ltd
- Target Recruit Count
- 34
- Registration Number
- NCT00879749
- Locations
- 🇦🇺
Q-Pharm Pty Ltd, Herston, Queensland, Australia
🇦🇺Nucleus Network - Centre for Clinical Studies, Melbourne, Victoria, Australia
© Copyright 2025. All Rights Reserved by MedPath